Article
Pharmacology & Pharmacy
Jiaqi Bi, Peiyu Sun, Erwei Feng, Jianxiong Shen, Chong Chen, Haining Tan, Zheng Li, Youxi Lin
Summary: This study demonstrated the synergistic therapeutic effects of melatonin and half-dose methylprednisolone for treating spinal cord injury. The combination of melatonin and half-dose methylprednisolone significantly reduced the dosage of methylprednisolone and limited its adverse reactions. The PI3K-AKT1 pathway was involved in the amelioration of acute SCI.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
W. -T. Chen, Y. -P. Zhou, G. -S. Zhang
Summary: Acute spinal cord injury (SCI) is a devastating disease that requires a multidisciplinary approach to treatment. Although the treatment of SCI has developed significantly, the use of steroids remains controversial due to limited clinical evidence. However, with the accumulation of evidence on the effectiveness of steroid treatment and the evidence of severe side effects, a gradual change in the treatment of SCI with steroids has become inevitable.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Liang-Yo Yang, Meng-Yu Tsai, Shu-Hui Juan, Shwu-Fen Chang, Chang-Tze Ricky Yu, Jung-Chun Lin, Kory R. Johnson, Hendrick Gao-Min Lim, Yang C. Fann, Yuan-Chii Gladys Lee
Summary: Through genomic analysis, the molecular effects of methylprednisolone (MP) in acute spinal cord injuries (SCIs) were explored, revealing three distinct classes: side effects, efficacy, and inability of MP. It was found that MP exerts its greatest effect at 8~12 hours post-injury in SCIs, with efficacy primarily in immune response and side effects involving metabolism and neurological processes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Clinical Neurology
Jose A. Canseco, Brian A. Karamian, Daniel R. Bowles, Michael P. Markowitz, Stephen L. DiMaria, Nicholas C. Semenza, Mark R. Leibensperger, Michael L. Smith, Alexander R. Vaccaro
Summary: The role of methylprednisolone in treating spinal cord pathologies such as acute spinal cord injury remains controversial, with some data supporting its benefits but also highlighting the risks of systemic adverse effects. Further research is needed to determine the effectiveness of steroids in treating patients with spinal cord pathology.
WORLD NEUROSURGERY
(2021)
Article
Clinical Neurology
Fred H. Geisler, Ali Moghaddamjou, Jamie R. F. Wilson, Michael G. Fehlings
Summary: The use of methylprednisolone (MP) to treat acute traumatic spinal cord injury (ATSCI) is controversial. Analysis of a new pooled ATSCI data set and an updated NASCIS2 data set revealed that MP did not enhance neurological recovery at 26 weeks. These findings need to be reviewed by clinical guideline groups.
JOURNAL OF NEUROSURGERY-SPINE
(2023)
Article
Neurosciences
Hamid Soltani Zangbar, Parviz Shahabi, Manouchehr Seyedi Vafaee, Tahereh Ghadiri, Abbas Ebrahimi Kalan, Solmaz Fallahi, Meysam Ghorbani, Mohsen Jafarzadehgharehziaaddin
Summary: Spinal Cord Injury (SCI) alters the hippocampal neurogenesis and rhythms, leading to decreased cell numbers and increased apoptotic cells. The power and max frequency of hippocampal rhythms significantly decline in injured animals.
BRAIN RESEARCH BULLETIN
(2021)
Article
Public, Environmental & Occupational Health
Yu Zhang, An-An Li, Shi-Ning Xiao, Nan-Shan Zhong, Wei-Lai Tong, Shi-Jiang Wang, Jia-Ming Liu, Zhi-Li Liu
Summary: This study conducted a bibliometric analysis of published literature on the treatment of spinal cord injury (SCI) using glucocorticoids. The research found that the use of methylprednisolone (MP) in treating SCI has increased over time, and emphasized the need for rigorous clinical trials to verify its therapeutic role and appropriate dosage.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Chemistry, Multidisciplinary
Bin Zhu, Guangjin Gu, Jie Ren, Xiaomeng Song, Junjin Li, Chunyan Wang, Wencan Zhang, Yanqing Huo, Haifeng Wang, Lin Jin, Shiqing Feng, Zhijian Wei
Summary: Spinal cord injury (SCI) leads to permanent loss of sensory and motor function, but effective clinical treatments are lacking. This study developed a non-invasive composite patch that releases exosomes and methylprednisolone to the injured spinal cord. The patch showed good biocompatibility, promoted macrophage polarization, reduced neuronal apoptosis, and inhibited inflammation in vitro and in vivo. These therapeutic effects are attributed to specific pathways. The composite patch offers a potential non-invasive treatment for SCI.
Article
Neurosciences
Hong-jun Zou, Shi-Wu Guo, Lin Zhu, Xu Xu, Jin-bo Liu
Summary: Methylprednisolone (MP) has shown significant protective effects in the treatment of traumatic spinal cord injury (TSCI), reducing neuronal damage and promoting neurological function recovery in TSCI mouse models.
FRONTIERS IN NEUROSCIENCE
(2021)
Article
Critical Care Medicine
Nader Hejrati, Bizhan Aarabi, Chris J. Neal, Beatrice Ugiliweneza, Shekar N. Kurpad, Christopher I. Shaffrey, James D. Guest, Elizabeth G. Toups, James S. Harrop, Michael G. Fehlings
Summary: Immunomodulatory therapeutics, such as methylprednisolone sodium succinate (MPSS), have shown potential neuroprotective effects in acute spinal cord injury (SCI). This study investigated the use of steroids in North American Clinical Trials Network (NACTN) centers from 2008 to 2018 and found a decrease in steroid use over time, possibly due to evolving literature and guidelines recommending against the use of MPSS for acute SCI.
JOURNAL OF NEUROTRAUMA
(2023)
Review
Orthopedics
Landon R. R. Bulloch, Leo Spector, Alpesh Patel
Summary: Central cord syndrome (CCS) is an incomplete spinal cord injury characterized by sensory and motor changes in the upper and lower extremities. While treatment methods are debated, diagnosis poses a challenge in accurately identifying this condition.
JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS
(2022)
Review
Clinical Neurology
Samira Saadoun, Nicolas D. Jeffery
Summary: Research on human and animal studies indicates that after severe spinal cord injury, the cord may swell against the inelastic dura. It has been suggested that durotomy could reduce cord pressure and inflammation in certain cases.
FRONTIERS IN NEUROLOGY
(2021)
Article
Clinical Neurology
Jacob Razzouk, Shaurya Mehta, Omar Ramos, Olumide Danisa, Wayne Cheng
Summary: This retrospective cohort study aimed to evaluate the incidence of litigation related to the use or omission of methylprednisolone, naloxone, or tirilazad for the treatment of acute spinal cord injury (ASCI) by querying the Westlaw and VerdictSearch databases. The study found that there is limited risk of malpractice litigation due to steroid use or lack thereof in ASCI treatment.
Article
Chemistry, Multidisciplinary
Xiao Zhai, Kai Chen, Xianzhao Wei, Hailing Zhang, Huan Yang, Kun Jiao, Chen Liu, Zhiguo Fan, Ji Wu, Tianjunke Zhou, Haojue Wang, Jingfeng Li, Ming Li, Yushu Bai, Bo Li
Summary: A new method using microneedles and a β-cyclodextrin metal-organic framework has been developed to deliver drugs to the spinal cord. These microneedles can generate micropores in the dura for direct drug delivery, and the CD-MOF provides extended release. In vitro and animal studies have shown that this method improves neurological function and reduces inflammation. This new drug platform has potential for clinical application in spinal cord diseases.
JOURNAL OF CONTROLLED RELEASE
(2023)
Article
Clinical Neurology
Tobias Zrzavy, Carmen Schwaiger, Isabella Wimmer, Thomas Berger, Jan Bauer, Oleg Butovsky, Jan M. Schwab, Hans Lassmann, Romana Hoeftberger
Summary: This study provides a detailed characterization of inflammatory responses and oxidative tissue injury in human traumatic spinal cord injury lesions. It reveals that ongoing inflammatory responses and neurotoxicity could lead to sustained neuronal damage long after the initial trauma, potentially impacting the response to rehabilitation and recovery in patients.
